Tofacitinib Citrate(CAS:540737-29-9) CAS NO.439081-18-2

Tofacitinib Citrate(CAS:540737-29-9)

 

Product Name: Tofacitinib Citrate

Other Name：1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1);1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);Tofacitinib citrate (CP-690550);Tofacitinib citrate;Tasocitinib citrate;Tasocitinib citric acid s...;Xeljanz;CP-690550 (Tofacitinib citrate)

CAS No.: 540737-29-9

Molecular Formula: C16H20N6O.C6H8O7

Molecular Weight: 504.497

Purity: 99%+

Product Specifications: Pharmaceutical Grade 

MOQ(Minimum Order Quantity): 100g

Payment: L/C, T/T,

Shipment: EMS, DHL, FedEx, TNT  

Brand: Newbio Pharm-Tech   

         

Product Description

Tofacitinib (formerly tasocitinib, CP-690550) is a drug being investigated for the treatment of rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. It is an inhibitor of the enzyme Janus kinase 3 (JAK3), which means that it interferes with the JAK-STAT signaling pathway that transmits information outside the cell into the cell nucleus, influencing DNA transcription. Recently it has been shown in a murine model of established arthritis, tofacitinib rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue. This efficacy in this disease model correlated with the inhibition of both JAK1 and 3 signaling pathways, suggesting that tofacitinib may exert therapeutic benefit via pathways that are not exclusive to inhibition of JAK3.

Tofacitinib citrate is currently approved for the treatment of rheumatoid arthritis.Tofacitinib citrate is an inhibitor of the enzyme janus kinase 3.

 

Tofacitinib Citrate(CAS:540737-29-9)

 

Product Name: Tofacitinib Citrate

Other Name：1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1);1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);Tofacitinib citrate (CP-690550);Tofacitinib citrate;Tasocitinib citrate;Tasocitinib citric acid s...;Xeljanz;CP-690550 (Tofacitinib citrate)

CAS No.: 540737-29-9

Molecular Formula: C16H20N6O.C6H8O7

Molecular Weight: 504.497

Purity: 99%+

Product Specifications: Pharmaceutical Grade 

MOQ(Minimum Order Quantity): 100g

Payment: L/C, T/T,

Shipment: EMS, DHL, FedEx, TNT  

Brand: Newbio Pharm-Tech   

         

Product Description

Tofacitinib (formerly tasocitinib, CP-690550) is a drug being investigated for the treatment of rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. It is an inhibitor of the enzyme Janus kinase 3 (JAK3), which means that it interferes with the JAK-STAT signaling pathway that transmits information outside the cell into the cell nucleus, influencing DNA transcription. Recently it has been shown in a murine model of established arthritis, tofacitinib rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue. This efficacy in this disease model correlated with the inhibition of both JAK1 and 3 signaling pathways, suggesting that tofacitinib may exert therapeutic benefit via pathways that are not exclusive to inhibition of JAK3.

Tofacitinib citrate is currently approved for the treatment of rheumatoid arthritis.Tofacitinib citrate is an inhibitor of the enzyme janus kinase 3.